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ABSTRACT
Given that mutated p53 (50% of all human cancers) is over-expressed in many 
cancers, restoration of mutant p53 to its wild type biological function has been 
sought after as cancer therapy. The conformational flexibility has allowed to restore 
the normal biological function of mutant p53 by short peptides and small molecule 
compounds. Recently, studies have focused on physiological mechanisms such as 
acetylation of lysine residues to rescue the wild type activity of mutant p53. Using p53 
null prostate cancer cell line we show that ID4 dependent acetylation promotes mutant 
p53 DNA-binding capabilities to its wild type consensus sequence, thus regulating 
p53-dependent target genes leading to subsequent cell cycle arrest and apoptosis. 
Specifically, by using wild type, mutant (P223L, V274F, R175H, R273H), acetylation 
mimics (K320Q and K373Q) and non-acetylation mimics (K320R and K373R) of p53, 
we identify that ID4 promotes acetylation of K373 and to a lesser extent K320, in turn 
restoring p53-dependent biological activities. Together, our data provides a molecular 
understanding of ID4 dependent acetylation that suggests a strategy of enhancing 
p53 acetylation at sites K373 and K320 that may serve as a viable mechanism of 
physiological restoration of mutant p53 to its wild type biological function.
INTRODUCTION
The somatic p53 missense mutations observed 
in almost half of all human cancers is a critical step 
in the oncogenic process [1, 2]. The consequences of 
p53 mutations (gain-of-function, GOF) within a cell 
can have at least three types of outcomes [3–6]: 1) p53 
mutations can abrogate the tumor suppressor function of 
the affected TP53 allele by reducing the overall capacity 
of the cell to mount a proper DNA damage response 
[6, 7], 2) the mutant p53 may exert dominant–negative 
effect over co-expressed wild type p53 by forming 
mixed tetramers that are incapable of DNA binding and 
transactivation [6, 8] and 3) the mutant p53 protein with 
activities of its own, can contribute to various aspects of 
tumor progression [6, 9, 10].
Mutant p53 can be classified into two groups: type 
I mutations, which affect amino acid residues directly 
involved in the DNA interaction (R248H, V274F, and 
R273H), and class II mutations involving residues 
responsible for stabilization of the three-dimensional 
structure of p53 [1, 11]. Structural mutants, includes the 
majority of p53 proteins found in human tumors, such 
as R175H, P223L, R249H, and R282H mutants, all of 
which destabilize p53 conformation and the p53 DNA-
binding [1, 2]. 
Structurally, wild type p53 consists of unfolded 
regions with high tendency for aggregation [12, 13]
Numerous studies of mutant p53 have been designed 
to explore whether the DNA binding capacity can be 
restored artificially by small molecules which can 
stabilize the interaction with DNA, by preventing mis-
folding or aggregation, site-specific phosphorylation and 
c- terminal amino acid substitution that mimics wild type 
p53 [2, 14–16]. Theoretical modeling of p53 has also been 
central to understanding the DNA-binding capabilities of 
mutant p53, as well as conformation changes induced 
by protein-protein interactions [17, 18]. The binding of 
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small molecules such as CP-31398 [19], ellipticine [20], 
MIRA-1 [21, 22], RITA [22], and PRIMA-1 [23] to mutant 
p53 proteins may induce wild type like conformational 
changes in the DNA binding domains of p53 mutant 
proteins, restoring sequence-specific p53 transcription 
[24]. In some cases, however, the mechanisms of activation 
is less understood, which provides a physiological basis of 
exploration into this phenomenon. 
Studies have shown that the all p53 mutations are 
not functionally equivalent [9]. The mutations in the DNA-
contacting residues of p53 have subtle effect on the folding 
of p53 protein as compared to the structural mutants [25]. 
The mutant p53 can also interact with transcription factors 
and recruited to respective binding sites of those factors 
on chromatin, and modulate their transcriptional output 
[26]. Incidentally, certain p53 mutants can activate similar 
genes known to be activated by wild type p53 and induce 
senescence or apoptosis in some cell types but not in 
others providing a physiologically relevant basis to study 
strategies, which can restore mutant p53 to wild type 
biological activity by non-artificial means. 
We and others have shown that in the case of 
wild type and mutant forms of p53, the interaction with 
acetylases and subsequent acetylation of p53 itself is 
indispensable for DNA binding and transcriptional activity 
such as the ability of p53 to trigger cell cycle arrest or 
apoptosis [1, 12, 27, 28]. Our previous study provided 
evidence that ID4, a helix loop helix transcriptional 
regulator recruited CBP/p300 (acetyltransferase) to promote 
large macromolecular assembly of p53 that could result in 
its acetylation and increased biological activity [28].
Here, we demonstrate that ID4, can promote p53-
dependent apoptosis and senescence in prostate cancer 
cells by specifically modifying the acetylation of p53, 
which increases its transcriptional activity and promotes 
the expression of pro-apoptotic and cell cycle regulatory 
genes. Furthermore, using acetylation mimics of mutant 
p53, we identify lysine 373 and to a lesser extent lysine 
320 as critical ID4 dependent acetylation sites that aid in 
p53 biological activities. Together, the results presented 
herein suggest that ID4 dependent p53 acetylation can 
be used as model to re-activate mutant p53 to wild type 
biological activity.
RESULTS
The PCa cell line PC3 was used to investigate 
ID4-p53 cross-talk. Specifically, we focused on the role 
of ID4 in regulating wild type and mutant p53 dependent 
apoptosis, senescence and transcriptional activity. The PC3 
cell line is null for p53 and has low endogenous levels of 
ID4 (Figure 1A).  Wild type p53 as well as various mutant 
p53 plasmids (P223l: PL, V274F: VF, P223L+V274F: 
VFPL, R273H and R175H) were over-expressed (stable 
and/or transient) in the cells. Following stable transfection 
and antibiotic selection the clones stably expressing wild 
type or mutant p53 (Figure 1B and 1C) were expanded for 
subsequent studies. 
Stable Silencing of ID4 and Expression of wild type 
and mutant P53 in PC3 cells: ID4 expression (Figure 1A) 
was undetectable or below detection limit in PC3 cells 
stably expressing the shRNA ID4 plasmid (PC3(-)ID4) 
(Figure 1B). As expected, p53 was not expressed in 
the PC3 cells transfected with empty vector (EV). The 
expression of wild type and mutant (PL, VF and VFPL) 
in PC3 and (PC3(-)ID4) suggested successful transfection 
and selection of the cell lines. The expression levels of 
the wild type and mutant p53 proteins in PC3 (Figure 1A) 
and PC3(-)ID4 (Figure 1B) was similar with the exception 
of VFPL mutant in PC3(-)ID4 (Figure 1B). The lower 
expression of VFPL mutant in PC3(-)ID4 could be due 
to multiple reasons e.g. destabilization of VFPL hetero-
tetramer in the absence of ID4. The results discussed 
below should therefore be interpreted in context of the 
observation that the combined VFPL mutant expression is 
comparatively lower in PC3(-)ID4 cells compared to the 
wild type and PL and VF p53 mutant.
ID4 promotes p53-mediated apoptosis
As expected a significant increase in apoptosis was 
observed in PC3+wild type p53 as compared to PC3 cells 
expressing the plasmid only control (EV) (Figure 1C, 
P < 0.001). The degree of apoptosis in PC3+wild type p53 
cells was then used to normalize the apoptosis observed 
in response to various mutant forms of p53 in PC3 with 
or without ID4 (%apoptotic index) (Figure 1C). In PC3 
cells, with the exception of VFPL which demonstrated a 
significant decrease in apoptosis (P < 0.001), the decrease 
in apoptosis of VF and PL was only marginal (75.3% and 
81.4% respectively) as compared to wild type p53 (set 
to 100%). Thus the two mutant forms of p53 (VFPL) 
expressed together (as expressed in DU145 cells) were less 
effective in promoting apoptosis (50.8%) as compared to 
wild type p53 or VF and PL mutants expressed separately 
(Figure 1C). These results suggest that VF and PL mutants 
retain most of the biological activity of the wild type p53.
The apoptotic index of PC3(-)ID4 with wild type 
p53 (64%) was significantly lower as compared to PC3 
cells with wild type p53 (100%, P < 0.05). Interestingly, a 
significantly lower apoptotic index was observed in PC3(-)
ID4 cells expressing PL and VF mutants (PL: 15.7% and 
VF: 18.1%, P < 0.001) as compared to PC3(-)ID4 cells 
with wild type p53 (100%) and as compared to PC3 cells 
with PL and VF mutants (75.3% and 81.4% respectively) 
(Figure 1C).The percentage apoptotic index in the double 
VFPL mutant (31.8%, P < 0.05) was higher compared 
to the mutants expressed individually in PC3(-)ID4. The 
results suggested that loss of ID4 leads to a decrease in 
apoptosis overall but has a significantly stronger effect on 
the apoptosis induced by the two mutant alone (VF and 
PL) as compared to the two mutants together (VFPL). 
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Thus, the results indicate that p53 promotes apoptosis in 
an ID4 dependent manner in PC3 cells. 
ID4 regulates expression of p53 targets genes
The expression of key downstream targets of p53 
were used to investigate the mechanism by which wild 
type and mutant p53 regulates apoptosis in the presence 
or absence of ID4.
The expression of cyclin dependent kinase inhibitor 
CDKN1A (p21), BAX and PUMA, which are well 
characterized p53 target genes increased in the presence of 
wild type and mutant p53 as compared to cells transfected 
with EV (Figure 2A) [29]. Interestingly, the expression 
of BAX between wild type p53 and PL mutant was 
essentially similar and higher than that observed in VF and 
VFPL. The expression profile of PUMA was also similar 
to that of BAX. The expression of p21 was similar between 
the wild type p53, PL and VF. The immunoblot analysis 
suggested that BAX, PUMA and p21 are expressed at a 
lower level in cells transfected with VFPL as compared 
to the PC3 cells transfected with these mutants alone. The 
expression level in VFPL correlates well with the extent of 
apoptosis in VFPL as compared to other p53 transfectants. 
The results suggested that similar to p53, the VF and PL 
mutants could be transcriptionally active. 
Loss of ID4 resulted in a significant decrease in the 
expression of all three p53 target genes in PC3(-)ID4 cells 
transfected with either wild type or mutant p53. These 
results suggested that ID4 expression may be required 
to promote the activation of p53 downstream targets, 
irrespective of the p53 mutations (Figure 2B). 
ID4 restores mutant p53 DNA binding and 
transcriptional activity
An ID4 dependent gain in p53 downstream 
targets lead us to investigate whether wild type and 
mutant p53 in PC3 cells regain DNA binding and 
transcriptional activity in an ID4 dependent manner. 
Based on an in vitro p53 DNA binding activity assay 
(using p53 response element immobilized on a 96 well 
Figure 1: Stable knockdown of ID4 by retroviral shRNA in PC3 cells and expression of wild type and mutant p53. (A) 
Expression of ID4 and p53 in PC3 cells following stable transfection with wild type and mutant p53 plasmids. (B) Expression of ID4 and 
p53 in PC3 cells in which ID4 was stably silenced ((PC3(-)ID4) followed by stable expression wild and mutant p53 plasmids. (C) ID4 
promotes p53-mediated apoptosis. Data represents apoptotic index calculated as percent of apoptosis as compared to apoptosis in PC3 
cells transfected with wild type p53 set to 100%.  A significant increase in apoptosis (***P < 0.001) in wild type and p53 mutants (p53 
mutants: P223L and V274F) as compared to PC3 (EV); “a” (P < 0.001) in PC3 (–)ID4 with various p53 mutants as compared to PC3(-)
ID4 cells transfected with wild type p53 and “b” (P < 0.001) and “c” (P < 0.05) is the statistical difference between PC3 and PC3(-)ID4 
cells transfected with the same wild type or mutant p53 plasmid. Abbreviations: EV: Empty vector, wild type: Wild Type, PL: P223L, VF: 
V274F, VFPL: V274F+P223L.
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plate followed by detection with p53 specific antibody) 
using nuclear extracts, a significant increase in p53 
DNA binding activity in the PC3+p53 (wild type and 
mutant p53) as compared the PC3(-)ID4 was observed 
(p < 0.001) (Figure 2C) with corresponding p53 wild type 
and mutant plasmids. The mutant VFPL p53 binding in 
PC(-)ID4 was significantly lowered as compared to wild 
type p53 and was comparable to EV. However, the DNA 
binding was also observed with VF and PL mutants in 
PC3 cells suggesting that these mutants are capable of 
DNA binding, possibly in the presence of ID4. No DNA 
binding was observed in the VFPL mutants which is 
consistent with the lack of its function (transactivation 
and apoptotic activity). 
We next performed a functional assay to further 
confirm the p53 transcriptional activity in PC3 cells. Using 
a p53 response element (wild type-p53RE) luciferase 
reporter plasmid assay, the relative p53 luciferase activity 
decreased significantly in PC3(-)ID4+p53 (wild type and 
mutant) as compared to PC3+p53 (wild type and mutant) 
cells (Figure 2D). Surprisingly, mutant p53 (PL and VF) 
also demonstrated moderately high luciferase activity 
in PC3 cells. The mutant p53 luciferase plasmid (mt-
p53RE) used as a negative control, as expected, did not 
Figure 2: ID4 regulates expression of p53 targets genes. (A) Protein expression of p21, BAX, and PUMA in PC3 and (B) PC3 
(-) ID4 cells expressing Empty vector (EV), wild type (wild type), and mutant p53 (PL: P223L, VF: V274F, VFPL: V274F+P223L). 
Representative western blots of three different experiments are shown. (C) Quantitative p53 DNA binding in a sandwich ELISA. ***:P < 0.001 
in wild type and p53 mutants as compared to PC3 (EV); “a” (P < 0.001) in PC3 (-)ID4 with various p53 mutants as compared to PC3(-)
ID4 cells transfected with wild type p53 and “b” (P < 0.001) is the statistical difference between PC3 and PC3(-)ID4 cells transfected with 
the same wild type or mutant p53 plasmid. 
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result in luciferase activity (Data not shown). In context of 
PC3+wild type p53 used as a positive control, our results 
strongly suggested that mutant p53 gains DNA binding 
and transcriptional activity in the presence of ID4.
ID4 promotes p53-mediated senescence
Having established that ID4 plays a critical role in 
modulating wild type and mutant p53 associated apoptosis, 
through the induction of a cell cycle checkpoint p21 
and apoptosis (BAX and PUMA), we next investigated 
whether p53 also regulates cellular senescence in an ID4 
dependent or independent manner. Senescence in normal 
cells is associated with a flattened, enlarged morphology 
with > 2-fold increase in cellular diameter compared to 
non-senescent cells [5]. 
The number of cells with strong (High) and those 
with light (Low-Moderate) blue staining were quantitated 
(Figure 3A). Over 60% of PC3 (wild type and mutant p53) 
cells stained positive for the SA-βgal and ~20% of those 
cells appeared to have flattened morphology (Figure 3A 
and 3B), indicative of senescence in PC3 (wild type and 
mutant p53) cells. The results summarized in (Figure 3B) 
demonstrated a significant increase in the number of cells 
with senescence associated beta-galactosidase (SA-βgal) 
staining in PC3 cells transfected with wild type p53 (High: 
81%, Low-Moderate 19.5%) as compared to EV (High: 
None, Low-Moderate: 5%, P < 0.001). A varying degree 
in SA-βgal staining was also observed in the PC3+PL/ VF 
or VFPL. Interestingly, senescence was not significantly 
different in PC3+PL but a disproportionate increase in 
cells with low-moderate senescence was observed in VF 
cells (91.6%, p < 0.001) with a corresponding decrease in 
cells with high senescence (8.42, p < 0.001) as compared 
to PC3+wild type p53 cells. The senescence in VFPL cells 
was not significantly different as compared to the PC3 
cells transfected with EV (Figure 3B). 
A significant increase in senescent cells was also 
observed in PC3(-)ID4 cells transfected with either 
wild type or mutant p53. Interestingly cells with high 
senescence were not observed in PC3(-)ID4+wild type p53 
cells but almost all cells showed low/moderate senescence. 
This is in stark contrast to PC3+wild type p53 cells in 
which a significant fraction of cells was highly senescent. 
The PL or VF mutants in PC3(-)ID4 also demonstrated 
low/ moderate senescence that was not significantly 
different from PC3(-)ID4+wild type p53 (Figure 3C). A 
decrease in the fraction of highly senescent PC3(-)ID4 
cells suggests that loss of ID4 expression down-regulates 
senescence at a higher frequency than PC3 cells (Figure 3)
The p53 hotspot mutants promotes apoptosis in 
an ID4 dependent manner
p53 hotspot mutants are known to not only lose their 
tumor-suppressor function but also acquire oncogenic 
gain of function (GOF) [30]. Studies on hotspot mutant 
p53 knock-in models have shown manifestation of GOF 
by broader tumor spectrum and more metastasis compared 
with non-hotpot p53 mutants and the p53-null allele, which 
have largely been the focus of this study [7, 25, 31]. We 
therefore examined whether ID4 would have a similar 
effect on hotspot p53 mutants as well. We investigated the 
rate of apoptosis in the presence of p53 hotspot mutations 
(R175H and R273H) in PC3 cells (Figure 4A). Surprisingly, 
the R175H mutant was able to induce apoptosis (apoptotic 
Index 56.6%, p < 0.001) as compared to vector only 
control (27.5%) but was significantly lower (p < 0.001) as 
compared to PC3+wild type p53 (apoptotic index 100%). 
The apoptotic index of the R273H mutant (41%) was not 
significantly different from the vector only control.
Interestingly, a significant decrease in apoptosis was 
observed in PC3(-)ID4 cells with R175H mutant (37.5%, 
P < 0.01) as compared to the corresponding PC3 cells with 
the same mutant (56.6%) and PC3(-)ID4 cells with wild 
type p53 (75.8%, p < 0.001). However there was not a 
significant decrease in apoptosis between PC3 and PC3(-)
ID4 cells with R273H mutant probably due to R273H 
classified as a DNA contact mutant.
The expression of p53 dependent apoptosis 
mediators is also consistent with the lower apoptotic index 
of R175H and R273H specifically. The expression of BAX 
in PC3 cells was in the following order p53 >> R175H 
> R273, whereas PUMA and p21 were not detected in 
PC3 cells with R273H (Figure 4B). In PC3(-)ID4 cells, 
the expression of all three p53 regulated genes was 
lower that their corresponding counterparts in PC3 cells 
however, BAX, PUMA and p21 was undetectable in in 
PC3(-)ID4+R273H (Figure 4C). These findings strongly 
suggested that ID4 can re-activate the function of well-
established p53 mutations.
ID4 promotes DNA binding and transcriptional 
activity of p53 hotspot mutants
We next investigated whether ID4 promotes DNA 
binding of the hotspot mutants in a p53 response element 
driven luciferase reporter assay. As shown in Figure 4D, 
the relative luciferase activity of R175H and R273H 
mutants in PC3 cells was significantly higher as compared 
to the empty vector control. The relative luciferase activity 
of R173H was significantly higher as compared to R273H 
(P < 0.001) whereas the relative luciferase activity of 
R173H (p < 0.01) and R273H (p < 0.001) was lower as 
compared to the relative luciferase activity of the wild type 
p53 (used as a positive control).
In PC3(-)ID4 cells, the relative luciferase activity 
of wild type (p < 0.001), R173H (P < 0.001) and R273H 
(P < 0.001) was significantly lower as compared to 
relative luciferase activity observed for the wild type p53 
in PC3 cells. Furthermore the relative luciferase activity 
of R173H and R273H in PC3(-)ID4 was significantly 
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lower (p < 0.001) as compared to the respective mutants 
in PC3 cells (Figure 4D). The mutant p53 luciferase 
plasmid (mt-p53RE) used as a negative control, as 
expected, did not result in luciferase activity (data not 
shown). These results clearly demonstrated that ID4 
regulates the transcriptional activity of the p53 hotspot 
mutants also. 
ID4 promotes acetylation of p53
To investigate the mechanism by which ID4 
may promote apoptosis and senescence, we explored 
the acetylation pattern on p53 in both PC3 and PC3(-)
ID4 cell lines (Figure 5). The total p53 protein was first 
immuno-precipitated and then immuno-blotted with 
antibodies specific against global p53 acetylation and 
K373 acetylation only. Our results demonstrated increased 
global p53 lysine acetylation as well as increased 
acetylation of K373 in PC3 cells (Figure 5A). Whereas 
we observed a significant decrease in both global and 
site specific (K373) acetylation of p53 in PC3 (-) ID4 
cells (Figure 5B). However, we were unable to observe 
significant global or site-specific acetylation (K373) in 
PC3 cells regardless of ID4 status with mutant p53-VFPL 
Figure 3: ID4 promotes p53-mediated senescence. (A) ID4 promotes senescence in PC3 cells expressing EV, wild type, and 
mutant p53 compared to PC3 (-) ID4. Representative images shown. (B) Quantitative representation of senescence ranging from None, 
Low/moderate, and High in PC3 cells expressing EV, wild type, and mutant p53. (C) Quantitative representation of senescence ranging 
from None, Low/moderate, and High in PC3 (-) ID4 cells expressing EV, wild type, and mutant p53. ***:P < 0.001 in wild type and p53 
mutants (p53 mutants: P223L and V274F) as compared to PC3 (EV); “a” (P < 0.001) in PC3 (-)ID4 with various p53 mutants as compared 
to PC3(-)ID4 cells transfected with wild type p53. Abbreviations: EV: Empty vector, wild type: Wild Type, PL: P223L, VF: V274F, VFPL: 
V274F+P223L.
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co-expressed compared to wild type and mutant p53 
(V274F and P223L) expressed individually (Figure 5). 
This is likely due to co-expression of both mutants, which 
is in line with previous studies which reported that upon 
co-expression, both mutants together lose capability to 
perform p53-mediated processes [32]. 
ID4 differentially modulates specific acetylation 
sites of p53
Next, we investigated the specific acetylation of p53 
within its C-terminal region that is known to regulate its 
stability and transcriptional activity, thereby facilitating 
Figure 4: The p53 Hotspot mutants promotes apoptosis in an ID4 dependent manner. (A, B) Protein expression profile of 
p21, BAX, and PUMA in PC3 and (C) PC3 (-) ID4 cells expressing EV, wild type, and hotspot mutant p53. Representative western blots of 
three different experiments are shown. (D) p53RE- luciferase reporter assay. A significant increase in apoptosis (***:P < 0.001, *:p < 0.05) 
in wild type and p53 mutants (p53 mutants: P223L and V274F) as compared to PC3 (EV); “a” (P < 0.001) in PC3 (-)ID4 with various p53 
mutants as compared to PC3(-)ID4 cells transfected with wild type p53 and “b” (P < 0.05) is the statistical difference between PC3 and 
PC3(-)ID4 cells transfected with the same wild type or mutant p53 plasmid. Abbreviations: EV: Empty vector, wild type: Wild Type, PL: 
P223L, VF: V274F, VFPL: V274F+P223L.
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active transcription of cell-cycle arrest, survival, or 
apoptotic gene programs [33]. However, the effects of 
acetylation and deacetylation on p53 activity seem to 
be cell-type dependent, and little is known about their 
consequence in epithelial cells of the prostate. Based on our 
earlier results that demonstrated ID4 dependent acetylation 
of K320 and K373 [28], we used an acetyl-mimic model 
to study the role of ID4 on site-specific residues critical 
to the regulation of p53 activity by using the acetylation 
and non-acetylation mimics (acetylation mimics: K320Q 
and K373Q and non-acetylation mimics: K320R and 
K373R) (Figure 6A). By overexpressing a collection of 
p53-R175H acetylation-mimic mutants in PC3 cells, our 
results suggest that specific acetylation at K373, and to 
a lesser extent at K320, are sufficient for inducing p53 
apoptosis (Figure 6B) and restoration of DNA-binding 
capabilities (Figure 6C). Interestingly, the results suggested 
the acetylation mimics (320Q and 373Q) on R173H 
backbone promoted apoptosis irrespective of ID4 expression 
(Figure 4A, 100% in PC3 and 84% in PC3(-)ID4). On the 
contrary, apoptosis was significantly reduced in the presence of 
the non-acetylation mimics (320R and 373R) in the presence 
(PC3: 49%) or absence of ID4 (41%, PC3(-)ID4) (Figure 6B). 
The R175H with the 320Q and 373Q acetylation mimics also 
demonstrated transactivation potential as determined by their 
relative luciferase activity. The non-acetylation mimics (320R 
and 373R) also demonstrated transactivation potential in PC3 
cells but not in PC3(-)ID4. But, in the absence of ID4, the 
lack of acetylation of flanking lysine could have resulted in 
the loss of activity of 320R and 373R in PC3(-)ID4. We then 
systematically evaluated the contribution or each acetylation 
site to understand their role on regulation the transactivation 
potential of R175H mutant in the absence of ID4.  Collectively, 
the results suggest that the apoptosis in PC3(-)ID4 cells with 
320Q and 373R mutant was significantly lower as compared 
to acetylation mimics. Furthermore the DNA binding activities 
with either of the K320 or K373 non-acetylation mutants was 
significantly lower in PC3(-)ID4 cells as compared to their 
activity in PC3 cells (Figure 6C). The results clearly suggested 
that these two acetylation sites may have an equal role on ID4 
dependent re-activation of the R175H p53.
DISCUSSION 
Current understanding of the complex biological 
processes regulated by the p53 tumor suppressor is still 
not clear [33, 34]. A number of studies in recent years have 
focused on the design of novel anticancer drugs that can re-
activate p53 mutants through various mechanisms [1, 35]. 
These studies raise the question of whether intracellular signals 
or pathways acting in a fashion similar to artificial compounds 
exist that can prevent mutant p53 loss of function [1]. In this 
study, we provide strong evidence that mutant p53 (DU145 
specific mutants P223L and V274F and hotspot p53 mutants 
R175H and R273H) gains DNA binding and trans-activation 
potential largely through ID4-dependent acetylation.
Previous reports have characterized p53 mutations 
in prostate cancer cell lines DU145 and PC3 [32, 36, 37]. 
DU145 cells harbor two missense mutations on both 
alleles (V274F and P223L) and PC3 is rendered null for 
p53 due to a frame-shift deletion [32]. The mutant form 
of p53 studied in the DU145 cell line shows activation 
of mutant forms of p53 due to a temperature sensitive 
allele. Flow cytometry studies found induced expression 
of P223L at 32C, but not at 37C, and was as active as wild 
type p53 in the inhibition of colony growth. The V274F 
allele had no growth-inhibitory effect suggesting that the 
P223L allele mediates the tumor suppressor phenotype. 
Moreover, the V274F allele did not promote reporter gene 
activity of p21 or HDM2, whereas the P223L did induce 
both respective p53 target genes expression, providing 
further evidence that the P223L allele may regain wild 
type p53 tumor suppressor phenotype possibly due to a 
change in structural conformation at lower temperature. 
These studies support the larger role for non-artificial 
intervention in restoring mutant p53 due to inherent 
conformational flexibility in p53. Taken together, these 
findings [37] and our previous studies [28] led us to 
continue our investigation of ID4 dependent acetylation 
on DU145 specific p53 mutants as well as hotspot p53 
mutations in p53-defecient cells of the prostate. 
Our studies suggest that the p53-mediated processes 
of V274F to be similar to that of the hotspot p53 mutants 
(R175H and R273H), suggesting that V274F more likely 
shares properties of “real” cancer-derived mutants as 
shown by Gurova et al. [32]. The V274F allele induced less 
apoptosis, senescence, and induction of p53 downstream 
targets compared to the P223L allele. Both P223L and 
V274F when expressed in PC3 cells, showed some 
properties that are unusual for tumor-derived mutants, as 
they both could be stabilized by DNA damage, suppress 
growth, and did not possess dominant–negative gain-of-
function activity, although, both mutants didn’t share the 
same rate of induction of these processes compared to one 
another, complimentary to both previous studies [32, 37]. 
Importantly, it was also shown when both relatively 
weak mutants were co-expressed in one cell they kept a 
predominantly denatured conformation, accumulated in 
large amounts in the cell, didn’t not show any increase 
after genotoxic stress, had no toxicity to any cells tested, 
and lacked transactivation function [32]. These findings 
align well with our results that show increased apoptosis 
and senescence with both relatively weak mutations 
individually. However, when both weak p53 mutants 
were co-expressed, we observed down regulation of p53-
depedent processes supporting previous studies [28, 32]. 
In our earlier studies, we proposed that ID4 dependent 
activation of mutant p53 in DU145 cells is mediated via 
acetyl-transferases such as CBP/p300 or by other post-
translational modifications that occur in an acetylation 
dependent manner. It has been well established that several 
C-terminal lysines (evolutionarily conserved across 
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species, [38]) of p53 (K370, K372, K373, K381, K382) are 
acetylated by CPB/p300 [39]. Acetylation of residues found 
in the C-terminal of p53 promotes an open conformation by 
promoting the ability of its C-terminus to bind and occlude 
the DNA binding domain, thereby activating and enhancing 
p53 transcriptional activity [39, 38]. 
Studies have shown that acetylation of p53 is 
usually activating but may also be repressive, that is 
largely cell type dependent [40, 41] . In human cancer cell 
lines, the p300-mediated acetylation of p53 is essential for 
p21 expression and cell cycle arrest [38] but not in mouse 
embryo fibroblasts (MEFs) lacking CBP/p300 [40]. 
Our results show ID4 dependent acetylation of 
p53 as activating, consequently the DU145 and hotspot 
p53 mutants transfected into PC3 gains trans-activation 
potential and DNA binding activity as compared to PC3 
cells that lack ID4. The gain of transactivation potential 
of mutant p53 in PC3 cells that express ID4 is supported 
by the observations that show increased p53 dependent 
luciferase reporter activity, direct DNA binding of mutant 
p53 and up-regulation of p53 target genes such as p21, 
BAX, and PUMA. Interestingly, BAX and in some cases 
p21 is not activated by most rumor derived p53 mutants 
[42]. However, our results suggest the p53 mutants 
overexpressed in PC3 cells expressing ID4 are capable 
of trans-activating not only p21, but BAX and PUMA as 
well. In contrast, PC3 cells that lack ID4, demonstrated 
decreased regulation of all aforementioned downstream 
targets and DNA-binding. These results strongly suggest 
that ID4 has a role in facilitating both DNA binding as 
well as trans-activation potential of mutant p53. Lastly, 
the ID4 dependent post-translation modifications within 
p53 (discussed below) provide a molecular basis for p53-
mediated modulation of transcriptional activity.
To elucidate the mechanism by which ID4 promotes 
p53-mediated transcriptional activity in PC3 cells we 
focused on ID4 dependent acetylation of p53. The results 
suggested an increased global p53 lysine and site-specific 
lysine (K373) acetylation in wild type and mutant p53 in 
an ID4 dependent manner, largely supporting our earlier 
studies in DU145 cells [28]. Moreover, we found no 
significant acetylation of mutant p53 (VFPL) when co-
expressed, regardless of ID4 status as compared to wild 
type and mutant p53 (V274F and P223L) expressed 
individually. Our data therefore is consistent with previous 
findings showing minimal trans-activation potential of 
both mutants when co-expressed [32, 37]. 
Acetyl-mimics were used as a model to study the 
effects of p53 acetylation and de-acylation (acetyl-mimics: 
K320Q/R and K373Q/R) by studying of site-specific 
residues critical to the regulation of p53 activity. By 
overexpressing a collection of acetylation-mimic on the 
p53-R175H backbone mutants in PC3 cells, we show that 
specific acetylation at K373, and to a lesser extent at K320, 
are sufficient for inducing p53 target gene dependent 
transactivation, apoptosis and restoration of DNA-binding 
capabilities in an ID4 dependent manner providing further 
evidence on the role of ID4 in modulating acetylation of 
p53. Interestingly, the inhibitory effect of deacetylation/
non-acetylation mimics (373R and 320R) on p53 induced 
apoptosis and DNA-binding capability seemingly disrupts 
the global transcriptional program of p53 by decreasing 
these activities. Moreover, ID4 may be preferentially 
modulating apoptosis and DNA-binding capabilities 
at higher rate via acetyl-mimic K373Q as compared to 
K320Q suggesting the K373 is critical for ID4 dependent 
p53 acetylation. Although not significant we did observe 
lower relative luciferase activity and apoptosis in K320R 
and K373R (deacytlation mimics) as compared to K320Q 
and K373Q acetyl-mimics in PC3 cells. Interestingly, 
Liu et al. [43] found similar results when they reported 
activation of downstream target a p21-thymidine kinase 
construct was modest (15%) with deacytlation mimics; 
this result might have been due to the presence of two 
flanking lysines (K319 and K321), one of which might be 
an optional binding site for PCAF [8], which could also 
provide an explanation of apoptotic activity and luciferase 
activity observed in our model with both K320R and 
K373R deacetylation mimics.
Apoptosis and to a lesser extent cell cycle arrest and 
senescence are largely regulated by acetylated p53 [44]. 
Several p53 null cell lines including PC3, upon treatment 
Figure 5: Acetylation of p53. (A) p53 immuno-precipitated from PC3 and (B) PC3(-) ID4 was blotted with antibodies against acetylated 
lysine (global) and p53 acetylated at K373 (Ac-320). An increase in interaction was observed in wild type and p53 mutants as compared to 
PC3 (EV) and decrease in interaction in PC3 (-) ID4 was observed in wild type and p53 mutants as compared to PC3(-) ID4 cells.
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with HDAC inhibitors that block the de-acetylation of 
p53 show induction of p21, but not BAX indicating a 
distinct role for acetylation dependent cell cycle arrest and 
senescence [45]. Studies indicating a role for acetylation 
dependent cell cycle arrest and senescence independent of 
p53 add an interesting and significant point of discussion to 
our study. It is plausible that ID4 mediated acetylation alone, 
can promote cell cycle arrest and senescence independent 
of p53, suggesting different ID4 dependent acetylation 
pathways. Moreover, recognition of p53-independent 
processes that effect cell cycle arrest and senescence provide 
a basis for future exploration into the possibility of ID4 
playing a larger role as a regulator of acetylation. Studies 
have also shown that stabilization of p53 at lysine 373, 
induces cell cycle arrest and apoptosis in LNCaP prostate 
cancer cells, while TSA an HDAC inhibitor stabilizes the 
Figure 6: (A) Schematic of p53-R175H Acetyl Mimics. (B) Comparative apoptotic index of acetylation mimics 320Q and 373Q 
on p53-R175H backbone in PC3 and PC3 (-) ID4 show significant decrease in apoptosis of 320Q-373R compared to 320Q-373R. ***:P 
< 0.001: between empty vector (EV) and acetylation mimics , wild type “a”: PC3 (-)ID4 and “b” (*p < 0.05) within the same transfectant 
between PC3 and PC3 (-)ID4 (C) Comparative p53RE-Lucifease reporter assay showed significant decrease in promoter binding in 
320Q-373R as compared to 320Q-373Q on the p53-R175H backbone in PC3 cells. (***:P < 0.001) was observed in wild type and p53 
mutants as compared to PC3 (EV) and “a”: PC3 (-)ID4 and “b” (**< 0.05) within the same transfectant between PC3 and PC3 (-)ID4. 
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acetylation of p53 at lysine 382 induces only cell cycle 
arrest in the cell line [12, 44]. Acetylation dependent cell 
fate determination in context of apoptosis and senescence 
via p53-mediated processes would be a promising study as 
possible mechanisms that lead to p53 directed cellular death 
or senescence are not well understood processes. 
Cell type differences also influence the role of 
acetylation in apoptosis. In HCT116 colorectal cells, 
loss of CBP/p300 dependent p53 acetylation leads to 
increased expression of PUMA and apoptosis following 
DNA damage, [46]. The acetylation at K381 and K382 
in neuronal cells also inhibits p53 binding to the PUMA 
promoter, preventing PUMA expression and DNA 
damage-induced cell death [47]. These results suggest that 
CBP/p300 expression normally suppresses p53-dependent 
apoptosis in neurons and HCT116 cancer cells.
As noted, studies have shown that the p53 mutations 
are indeed not all functionally equivalent, hence reports 
of p53 mutants with differential effects on the cell [9]. In 
the context of our study, p53 mutants in PC3 cells that 
express ID4 are able to promote p21, BAX, and PUMA 
expression. At least two of the p53 hotspot mutants 
R175H and R273H, which are well known cancer-derived 
gain-of-function p53 mutants accounting for 15% of all 
p53 mutations in cancer and have been shown to have 
crippling effects on knock-in mouse models [8, 48, 49]. 
Taken together, this study supports exploring a profile 
of other known p53 hotspot mutants and study of their 
inherent structural flexibility in context of acetylation.
In conclusion, our present study finds that ID4 plays a 
pivotal role in modulation of acetylation and preferentially 
acts to acetylate K373 for transactivation of p53 in context 
of both DU145 specific p53 mutants and hotspot mutants 
overexpressed in PC3 cells. This phenomenon provides 
clear evidence that ID4 may serve as a physiological agent 
to restore p53 wild type function to various mutant forms of 
p53 in a non-cell line/non-mutation specific manner. While 
this data is intriguing, it is of great interest to determine 
if this phenomenon of p53 restoration via ID4 is effective 
in other organ systems (outside prostate cancer) as well as 
with a variety of other p53 mutations. Continued studies 
elucidating the mechanism of action will help to unravel 
the complex biological processes of ID4 and p53 in cancer. 
The strong anti-cancer effect of ID4 previously reported 
in prostate cancer and cross-talk with p53 will provide 
a strong framework of study in other systems, which 
eventually could serve as an attractive therapeutic approach 
[50]. ID4 promotes acetylation possibly by recruiting 
CBP/P300 type acetyl transferases however whether other 
acetyltransferases can also be recruited by ID4 independent 
of p53 for other proteins remains to be investigated. In the 
future, the studies demonstrating the effect of ID4 as a 
tumor suppressor in which certain acetyl transferases have 
been silenced (in the absence or presence of wild type or 
mutated p53) may help to unravel the complex mechanism 
of action of ID4. 
MATERIALS AND METHODS
ID4 silencing in prostate cancer (PCa) cell line
PC3 prostate cancer cell line was purchased from 
ATCC and cultured as per ATCC recommendations. 
ID4 was stably silenced in PC3 cells using gene specific 
shRNA retroviral vector as described earlier [28].
Mutagenesis of p53: The retroviral p53 vector 
previously described [28] was manipulated via mutation 
induced by site-directed mutagenesis mimicking DU145 
cells that harbor mutant p53 (P223L and V274F) [51] via 
QuickChange II Site-Directed Mutagenesis kit (Agilent 
Technologies, USA). Hotspot mutations of p53 (R273H and 
R175H) [52] were purchased from Addgene, Inc: pCMV-
Neo-Bam p53 R175H (Addgene plasmid #16436) and 
pCMV-Neo-Bam p53 R273H (Addgene plasmid # 16439) 
[53] was a gift from Bert Vogelstein. The following primers 
were used for generating the P223L and V274F mutants:
Primers for P223L mutant
Forward: 5ʹ-CTA TGA GCC GCC TGA GGT TGG 
CTC TG
Reverse: 5ʹ-CAG AGC CAA CCT CAA GCG CAT 
AG
Primers for V274F mutant:
Forward: 5ʹ AGG TGC GTG TTT GTG CCT GTC 
CTG G
Reverse: 5ʹ CCA GGA CAG GCA CAA AAA CGC 
ACC T
The following primer pair was used for reverse 
transcriptase polymerase chain reaction (RT-PCR) and 
sequencing of p53 for measuring expression levels and 
verifying the mutants by sequencing the PCR product:
P53 wild type
Forward 5ʹ-GCT CAG ATA GCG ATG GTC TG 
Reverse: 5ʹ TCT TCT TTG GCT GGG GAG AG
Western Blot Analysis: 30 ug of total protein, 
extracted from cultured prostate cancer cell lines using 
M-PER (Thermo Scientific) was size fractionated on 
4–20% SDS-polyacrylamide gel. The fractionated 
proteins were transferred onto a nitrocellulose membrane 
(Whatman) and subjected to western blot analysis using 
respective protein specific antibodies. After washing with 
1x PBS, 0.5% Tween 20, the membranes were incubated 
with horseradish peroxidase (HRP) coupled secondary 
antibody against rabbit IgG and visualized using the Super 
Signal West Dura Extended Duration Substrate (Thermo 
Scientific) on Fuji Film LAS-3000 Imager.
Apoptosis assay
Apoptosis was quantified using Propidium Iodide 
and Alexa Fluor 488 conjugated Annexin V (Molecular 
Probes) as described previously [54]. 
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Senescence associated (SA)-β-galactosidase assay
The senescence associated-β-galactosidase assay 
was performed essentially as described earlier [55]. Briefly, 
the cells were cultured in six well plates with respective 
media. The cells at 60–70% confluency were stained for 
senescence associated-β-galactosidase (SA-βgal) staining 
kit (Cell signaling) as per manufacturer’s instructions. At 
least 15 representative fields were randomly selected for 
the quantitation of the percentage of SA-βgal positive cells. 
The images were captured in both phase contrast and bright 
field to better visualize cellular details.
p53 Activity Assay
p53 DNA binding activity and quantitation on nuclear 
extracts was performed as described previously [28].
Transient transfections and reporter gene assay
PC3 cells cultured in 96-well plates (70–80% 
confluency) were transiently transfected with reporter 
plasmids by FuGENE HD transfection reagent (Promega) 
as described earlier [28]. Briefly, the PG13-luc (containing 
13 copies of wild type p53 binding sites [26], Addgene) or 
MG15-luc (containing 15 mutant p53 binding sites [26], 
Addgene) with pGL4.74 (hRluc/TK: Renilla luciferase, 
Promega) plasmid DNA was transfected in a 10:1 ratio. 
After 24 h, the cells were assayed for Firefly and Renilla 
luciferase activities using the Dual- Glo Luciferase 
reporter assay system (Promega) in LUMIstar OPTIMA 
(MHG Labtech). The results were normalized for the 
internal Renilla luciferase as control.
Co-immunoprecipitation
Co-immunoprecipitations were performed to 
detect the protein-protein interactions. Briefly, protein 
specific IgG (anti-p53 or –ID4) was first immobilized to 
Protein A Mag beads by incubating overnight at 4C as 
per manufacturer’s instructions (Protein A Mag beads, 
GenScript). The co-elution of IgG following immuno-
precipitation was minimized by cross linking, IgG on 
protein A mag beads as described in the kit. To detect 
protein interactions, the cross-linked protein specific IgG-
protein A-Mag beads were incubated overnight (4C) with 
freshly extracted total cellular proteins (500 µg/ml). The 
complex was then eluted with 0.1M Glycine buffer (pH 
2–3) after appropriate washing with PBS and neutralized 
by adding neutralization buffer (1M Tris, pH 8.5). 
Generation of acetyl-p53 mimics constructs
Plasmids containing sequences for human p53-
R175H DNA-binding mutants: K320R+K373R, 
K320Q+K373Q, K320R+K373Q, and K320Q+K373R 
were commercially synthesized (GenScript). The 
following primers were used:
Lysine 373 Non-Acetylation Mimic
Forward: K373R 5ʹ-CAC CTG AAG TCC AAA 
AGG GGT CAG TCT ACC TCC
Reverse: K373R 5ʹ-GGA GGT AGA CTG ACC 
CCT TTT GGA CTT CAG GTG
Lysine 373 Acetylation Mimic
Forward: K373Q 5ʹ-CAC CTG AAG TCC AAA 
GAG GGT CAG TCT ACC TCC
Reverse: K373Q 5ʹ-GGA GGT AGA CTG ACC 
CTC TTT GGA CTT CAG GTG
Lysine 320 Non-Acetylation Mimic
Forward: K320R 5ʹ-TCT CCC CAG CCA AAG 
AGG AAA CCA CTG GAT GGA
Reverse: K320R 5ʹ-TCC ATC CAG TGG TTT CCT 
CTT TGG CTG GGG AGA
Lysine 320 Acetylation Mimic
Forward: K320Q 5ʹ-TCT CCC CAG CCA AAG 
GAG AAA CCA CTG GAT GGA
Reverse: K320Q 5ʹ-TCC ATC CAG TGG TTT CTC 
CTT TGG CTG GGG AGA
Statistical analysis
Data was analyzed by SPSS 13.0 statistics software. 
Experimental data is presented as means ± standard error 
of the mean (SEM). A p-value of < 0.05 was considered 
statistically significant. 
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